Yong Yu - 17 Nov 2023 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
17 Nov 2023
Transactions value $
-$210,431
Form type
4
Filing time
21 Nov 2023, 16:15:27 UTC
Previous filing
25 Oct 2023
Next filing
22 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Sale -$46,169 -3,541 -3.34% $13.04 102,594 17 Nov 2023 Direct F1
transaction GNLX Common Stock Sale -$164,261 -14,594 -14.2% $11.26 88,000 20 Nov 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $13.0386, and the range of prices were between $13.00 and $13.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F2 The weighted average sale price for the transaction reported was $11.2554, and the range of prices were between $11.00 and $11.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.